Study of combined methotrexate and phototherapy in vitiligo.

Study of methotrexate with phototherapy on vitiligo patients in comparison with phototherapy alone.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221013056158N1

Enrollment

Registered

2022-12-11

Start date

2021-03-21

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo.

Interventions

Intervention 1: Intervention group: Vitiligo patients in this group received phototherapy twice a week and oral methotrexate 12/5 milligrams in a week. Intervention 2: Control group: Vitiligo patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Known case of vitiligo No systemic or local immunosuppressive treatment in past 6 months Vitiligo disease activity more than one Candidates for phototherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of vitiligo disease. Timepoint: Before treatment, after 2 months, 4 months and 6 months of treatment. Method of measurement: Vitiligo Area Scoring Index.;Vitiligo activity. Timepoint: Before treatment then after 2 months, 4 months and 6 months of treatment. Method of measurement: Vitiligo Disease Activity Scorings.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahrasadat Seyedhoseini

Tehran University of Medical Sciences

hoseini9020@yahoo.com+98 21 5560 9952

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026